Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing

Blood

Volumn 122, Issue 19, 2013, Pages 3308-3316

  Dubovsky, Jason A ^a   Chappell, Danielle L ^a   Harrington, Bonnie K ^b   Agrawal, Kitty ^c   Andritsos, Leslie A ^a   Flynn, Joseph M ^a   Jones, Jeffrey A ^a   Paulaitis, Michael E ^c   Bolon, Brad ^d   Johnson, Amy J ^a   Byrd, John C ^a,b   Muthusamy, Natarajan ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Ohio State University   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; F ACTIN; IBRUTINIB; IDELALISIB; IMMUNOGLOBULIN G; LYMPHOCYTE CYTOSOLIC PROTEIN 1; MEMBRANE ANTIGEN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CXCL12 PROTEIN, HUMAN; LCP1 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEOME; STROMAL CELL DERIVED FACTOR 1; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VIVO STUDY; LEUKEMIA CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CROSS LINKING; TUMOR IMMUNITY; TUMOR XENOGRAFT; ANIMAL; B LYMPHOCYTE; BIOTINYLATION; BONE MARROW TRANSPLANTATION; CELL MEMBRANE; CELL MOTION; CLINICAL TRIAL; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROTEIN BINDING; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT; ANTAGONISTS AND INHIBITORS; DEFICIENCY;

ANIMALS; B-LYMPHOCYTES; BIOTINYLATION; BONE MARROW TRANSPLANTATION; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CHEMOKINE CXCL12; EXOSOMES; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, SCID; MICROFILAMENT PROTEINS; PROTEIN BINDING; PROTEOME; RECEPTORS, ANTIGEN, B-CELL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84888239769     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-504597     Document Type: Article

References (32)

1. Kay NE, Rai KR, O’Brien S. Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol. 2006;4(11 Suppl 22):1-10, quiz 11-12.
2. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010;116(19):3705-3714.
3. Jain P, O’Brien S. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opin Biol Ther. 2013;13(2):169-182.
4. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010; 115(13):2619-2629.
5. Dubovsky JA, Albertini MR, McNeel DG. MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis. J Immunother. 2007;30(7):675-683.
6. Dubovsky JA, McNeel DG. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate. 2007;67(16):1781-1790.
7. Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J, Sotomayor EM. Circumventing immune tolerance through epigenetic modification. Curr Pharm Des. 2010;16(3): 268-276.
8. Fukuda T, Chen L, Endo T, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA. 2008;105(8): 3047-3052.
9. Hudecek M, Schmitt TM, Baskar S, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010; 116(22):4532-4541.
10. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:96-103.
11. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175-1184.
12. Byrd JC, Furman RR, Coutre S, et al. The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. ASH Annual Meeting Abstracts. 2012;120(21):189.
13. Landau DA, Wu CJ. Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 2013; 5(5):47.
14. Perrot A, Pionneau C, Nadaud S, et al. A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. Blood. 2011;118(4):e1-e15.
15. Lapalombella R, Yeh YY, Wang L, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012;21(5):694-708.
16. Dubovsky JA, Wang D, Powers JJ, et al. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res. 2011;35(3):394-404.
17. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2): 166-180.
18. Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res. 1999;59(5): 1003-1007.
19. Nitta T, Sugihara K, Tsuyama S, Murata F. Immunohistochemical study of MUC1 mucin in premalignant oral lesions and oral squamous cell carcinoma: association with disease progression, mode of invasion, and lymph node metastasis. Cancer. 2000;88(2):245-254.
20. Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci USA. 2009;106(33):14010-14015.
21. Bu N, Wu H, Sun B, et al. Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma. J Neurooncol. 2011;104(3):659-667.
22. Schorey JS, Bhatnagar S. Exosome function: from tumor immunology to pathogen biology. Traffic. 2008;9(6):871-881.
23. Morley SC. The actin-bundling protein L-plastin: a critical regulator of immune cell function. Int J Cell Biol. 2012;2012:935173.
24. Samstag Y, Klemke M. Ectopic expression of L-plastin in human tumor cells: diagnostic and therapeutic implications. Adv Enzyme Regul. 2007;47:118-126.
25. Al Tanoury Z, Schaffner-Reckinger E, Halavatyi A, et al. Quantitative kinetic study of the actin-bundling protein L-plastin and of its impact on actin turn-over. PLoS ONE. 2010;5(2):e9210.
26. Klemke M, Rafael MT, Wabnitz GH, et al. Phosphorylation of ectopically expressed L-plastin enhances invasiveness of human melanoma cells. Int J Cancer. 2007;120(12): 2590-2599.
27. Lin CS, Park T, Chen ZP, Leavitt J. Human plastin genes. Comparative gene structure, chromosome location, and differential expression in normal and neoplastic cells. J Biol Chem. 1993;268(4): 2781-2792.
28. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol. 2004;82: 249-293.
29. Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother. 1998;46(5): 245-252.
30. Agrawal B, Reddish MA, Krantz MJ, Longenecker BM. Does pregnancy immunize against breast cancer? Cancer Res. 1995;55(11):2257-2261.
31. Aalto Y, El-Rifa W, Vilpo L, et al. Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion. Leukemia. 2001; 15(11):1721-1728.
32. Freeley M, O’Dowd F, Paul T, et al. L-plastin regulates polarization and migration in chemokine-stimulated human T lymphocytes. J Immunol. 2012;188(12):6357-6370.